Levonorgestrel-releasing intrauterine system (mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia

Journal of Research in Medical Sciences

Volumn 19, Issue 8, 2014, Pages 686-690

  Behnamfar, Fariba ^a   Ghahiri, Attaollah ^b   Tavakoli, Marzieh ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Endometrial hyperplasia; Levonorgestrel releasing intrauterine system; Medroxyprogesterone

Indexed keywords

CHOLESTEROL; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOATING; BODY WEIGHT DISORDER; COMORBIDITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; FATIGUE; FEMALE; HAIR LOSS; HIRSUTISM; HISTOPATHOLOGY; HUMAN; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

EID: 84911486053     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Karimi-Zarchi M, Dehghani-Firoozabadi R, Tabatabaie A, Dehghani-Firoozabadi Z, Teimoori S, Chiti Z, et al. A comparison of the effect of levonorgestrel IUD with oral medroxyprogesterone acetate on abnormal uterine bleeding with simple endometrial hyperplasia and fertility preservation. Clin Exp Obstet Gynecol 2013;40:421-4.
2. Horn LC, Schnurrbusch U, Bilek K, Hentschel B, Einenkel J. Risk of progression in complex and atypical endometrial hyperplasia: Clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer 2004;14:348-53.
3. Orbo A, Arnes M, Pettersen I, Larsen K, Hanssen K, Moe B. Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system. Acta Obstet Gynecol Scand 2010;89:1438-46.
4. Buttini MJ, Jordan SJ, Webb PM. The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: An Australian study and systematic review. Aust N Z J Obstet Gynaecol 2009;49:316-22.
5. Wildemeersch D, Dhont M. Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system. Am J Obstet Gynecol 2003;188:1297-8.
6. Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 2002;186:651-7.
7. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: A systematic review and metaanalysis. Am J Obstet Gynecol 2010;203:547.e1-10.
8. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997;90:434-40.
9. Crosignani PG, Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod 2006;21:248-56.
10. Schlaff WD, Carson SA, Luciano A, Ross D, Bergqvist A. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril 2006;85:314-25.
11. Lähteenmäki P, Rauramo I, Backman T. The levonorgestrel intrauterine system in contraception. Steroids 2000;65:693-7.
12. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol (Oxf) 1982;17:529-36.
13. Hurskainen R, Teperi J, Rissanen P, Aalto AM, Grenman S, Kivelä A, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: Randomized trial 5-year follow-up. JAMA 2004;291:1456-63.
14. Pashov AI, Diduk OV. The nature of a cancer of a body of a uterus in Krasnoyarsk edge. Obstetrics and Gynecology Pressing Questions: The Collection of Proceedings. Krasnoyarsk; 2009. p. 93-8.
15. Surrey ES, Hornstein MD. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: Long-term follow-up. Obstet Gynecol 2002;99:709-19.
16. Lindahl B, Alm P, Fernö M, Norgren A. Endometrial hyperplasia: A prospective randomized study of histopathology, tissue steroid receptors and plasma steroids after abrasio, with or without high dose gestagen treatment. Anticancer Res 1990;10:725-30.
17. Vereide AB, Arnes M, Straume B, Maltau JM, Ørbo A. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: A study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 2003;91:526-33.
18. I smail MT, Fahmy DM, Elshmaa NS. Efficacy of levonorgestrel-releasing intrauterine system versus oral progestins in treatment of simple endometrial hyperplasia without atypia. Reprod Sci 2013;20:45-50.
19. Ørbo A, Arnes M, Hancke C, Vereide AB, Pettersen I, Larsen K. Treatment results of endometrial hyperplasia after prospective D-score classification: A follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol 2008;111:68-73.